The seemingly detrimental effect on OS of patients with NASH- or NAFLD-HCC by anti-PD-1/L1 antibody treatment may be related to impaired immune surveillance by exhausted hepatic CD8+PD-1+ T cells (Pfister et al., 2021). This evidence concerns the gene CD8A and hepatocellular carcinoma.